Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Research analysts at Oppenheimer lifted their Q2 2019 earnings per share estimates for shares of Biohaven Pharmaceutical in a report issued on Wednesday, June 19th. Oppenheimer analyst E. Rajavelu now forecasts that the company will earn ($1.40) per share for the quarter, up from their previous estimate of ($1.62). Oppenheimer currently has a “Buy” rating and a $68.00 target price on the stock. Oppenheimer also issued estimates for Biohaven Pharmaceutical’s Q3 2019 earnings at ($1.70) EPS, Q4 2019 earnings at ($1.61) EPS, FY2019 earnings at ($6.13) EPS and FY2020 earnings at ($6.36) EPS.
A number of other research analysts have also recently commented on the company. Morgan Stanley cut Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and set a $49.13 price objective on the stock. in a report on Tuesday, April 9th. They noted that the move was a valuation call. Goldman Sachs Group initiated coverage on Biohaven Pharmaceutical in a report on Monday, May 6th. They issued a “buy” rating and a $92.00 price objective on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $84.00 price objective (down from $89.00) on shares of Biohaven Pharmaceutical in a report on Tuesday. Needham & Company LLC upped their price objective on Biohaven Pharmaceutical to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 8th. Finally, Cantor Fitzgerald upped their price objective on Biohaven Pharmaceutical to $82.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $69.55.
BHVN opened at $39.79 on Monday. Biohaven Pharmaceutical has a one year low of $29.17 and a one year high of $67.86. The firm has a market capitalization of $1.77 billion, a PE ratio of -6.47 and a beta of 0.72. The firm has a 50 day simple moving average of $58.02.
Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) EPS for the quarter, beating analysts’ consensus estimates of ($1.50) by $0.09. During the same period last year, the firm earned ($2.32) earnings per share.
In other Biohaven Pharmaceutical news, Director Declan Doogan sold 88,825 shares of the company’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $58.42, for a total transaction of $5,189,156.50. Following the transaction, the director now directly owns 373,913 shares in the company, valued at $21,843,997.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.90% of the stock is owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in BHVN. Rhumbline Advisers boosted its position in shares of Biohaven Pharmaceutical by 52.1% during the 4th quarter. Rhumbline Advisers now owns 36,745 shares of the company’s stock valued at $1,359,000 after acquiring an additional 12,587 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Biohaven Pharmaceutical during the 4th quarter valued at about $507,000. BlackRock Inc. boosted its position in shares of Biohaven Pharmaceutical by 10.4% during the 4th quarter. BlackRock Inc. now owns 2,393,148 shares of the company’s stock valued at $88,499,000 after acquiring an additional 225,386 shares during the last quarter. Citigroup Inc. boosted its position in shares of Biohaven Pharmaceutical by 38.9% during the 4th quarter. Citigroup Inc. now owns 92,861 shares of the company’s stock valued at $3,434,000 after acquiring an additional 26,019 shares during the last quarter. Finally, Blueshift Asset Management LLC bought a new stake in shares of Biohaven Pharmaceutical during the 4th quarter valued at about $306,000. Institutional investors own 90.39% of the company’s stock.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.